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In Malaysia, breast cancer is the most common cancer where 1 in 19 
Malaysian women will be diagnosed with breast cancer by the age of 85. Moreover, 
lack of specific symptoms in the early stage of disease leading to delay in diagnosis. 
Unfortunately, current treatments by chemotherapeutic agents, surgery and radiation 
are not fully effective for the treatment of breast cancer. Thus, there is an urgency in 
developing new approaches for the treatment of breast cancer patients. In this study, 
a novel therapeutic regimen, combining the effects of recombinant adenovirus and 
hyperthermia was investigated. Firstly, Adenovirus serotype 5 was constructed by 
cloning of p53 gene into a defective recombinant adenovirus vector, Ad5-p53-DsRed 
Monomer N1. The Ad5-p53-DsRed Monomer N1 (MOI of 100) was then used to 
infect breast cancer cells (MDA-MB 231 and MCF-7) with or without combination 
of hyperthermia treatment (42ºC for 2 hours). The cell killing and viral concentration 
were then determined by MTT assay and viral plaque formation assay respectively. 
After that, the heat shock protein (Hsp70) and p53 protein expression in transfected 
cells were quantitated using ELISA assay. Activated-Caspase 3/7, 8 and 9 were also 
evaluated to study the apoptotic pathway of cancer cells. Furthermore, the novel 
protein interaction between nucleotide binding domain (NBD) Hsp70 and human 
Ad5 E1A 32 kDa motif (PNLVP); and NBD and p53 motif (SCMGGMNR) were 
investigated through bioinformatics tools such as Gromacs and Autodock softwares. 
It was found that MDA-MB 231 and MCF-7 cells infected with virus Ad5-p53-
DsRed Monomer N1 alone resulted in 46.77±2.74% and 42.26±1.78% cell killing 
respectively while hyperthermia in combination with virus were 84.82±1.64% and 
80.13±3.30% respectively. The Hsp70 expression of both cancer cells was also 
increased to 170.57% (MDA-MB 231) and 169.83% (MCF-7). Moreover, p53 
expression in MDA-MB 231 and MCF-7 cells by virus combined with heat treatment 
(85.72 ng/L and 79.05 ng/L respectively) could lead to enhanced oncolytic property 
compared to virus treatment alone (47.82 ng/L and 40.54 ng/L respectively). In 
addition, caspase activity was first time reported that apoptosis process started at 
very early stage of infection in breast cancer cells with hyperthermia compared to 
virus alone. This was due to the evident that the highest kinetic energy was found in 
caspase 3 whereas virus alone the highest in caspase 8.  In conclusion, Hsp70 
induction by hyperthermia treatment enhanced Ad5-p53-DsRed Monomer N1 
replication and oncolysis in MDA-MB 231 and MCF-7 cells through apoptotic 
pathway. Besides that, NBD of Hsp70 had the best interaction with PNLVP motif at 
42°C. Thus, combining Ad5-p53 with hyperthermia treatment could be a potential 


















Di Malaysia, kanser payudara adalah kanser yang paling umum dimana 1 
dalam 19 wanita Malaysia akan didiagnosis dengan kanser payudara menjelang usia 
85. Tambahan pula, kekurangan tanda-tanda spesifik di peringkat awal penyakit yang 
membawa kepada kelewatan dalam diagnosis. Malangnya, rawatan semasa dengan 
agen kemoterapi, pembedahan dan radiasi tidak berkesan sepenuhnya untuk merawat 
kanser payudara. Oleh itu, strategi baru diperlukan dengan segera untuk merawat 
pesakit kanser payudara. Dalam kajian ini, potensi untuk mengabungkan regimen 
terapeutik novel adenovirus rekombinan dan „hyperthermia‟ telah dikaji. 
Pertamanya, Adenovirus jenis 5 telah dibangunkan dengan pengklonan gen p53 ke 
dalam vektor adenovirus rekombinan, Ad5-p53-DsRed Monomer N1. Kepekatan 100 
PFU bagi Ad5-p53-DsRed Monomer N1 telah digunakan untuk menjangkiti sel-sel 
kanser payudara (MDA-MB 231 dan MCF-7) dengan atau tanpa digabungkan 
dengan rawatan hyperthermia (42ºC selama 2 jam). Kemudian, tahap kemusnahan sel 
dan kepekatan virus telah ditentukan dengan asai MTT dan asai pembentukan plak 
virus. Selepas itu, pengekspresan protein kejutan haba (Hsp70) dan p53 dalam sel 
telah dianalisis dengan menggunakan asai ELISA. „Caspase‟ teraktif  3/7, 8 dan 9 
juga telah dikaji untuk tapak jalan apoptosis sel kanser. Tambahan pula, interaksi 
protein novel di antara domain pengikat nukleotida (NBD) bagi Hsp70 dan motif 
Ad5 E1A 32 kDa (PNLVP); dan NBD dan motif p53 (SCMGGMNR) telah dikaji 
dengan kaedah bioinformatik seperti perisian Gromacs dan Autodock. Kajian ini 
menunjukkan bahawa MDA-MB 231 dan MCF-7 yang dijangkiti virus Ad5-p53-
DsRed Monomer N1 sahaja menyebabkan 46.77 ± 2.74% dan 42.26 ± 1.78% sel 
musnah manakala „hyperthermia‟ dengan virus adalah 84.82 ± 1.64% dan 80.13 ± 
3.30% masing-masing. Pengekspresan protein Hsp70 bagi kedua-dua sel kanser juga 
meningkat kepada 170.57% (MDA-MB 231) dan 169.83% (MCF-7). Selain itu, 
pengekspresan protein p53 dalam MDA-MB 231 and MCF-7 bagi gabungan virus 
dan „hyperthermia‟ adalah 85.72 ng/L dan 79.05 ng/L masing-masing manakala 
perlakuan virus sahaja adalah 47.82 ng/L dan 40.54 ng/L masing-masing. Aktiviti 
„caspase‟ telah dilaporkan kali pertamanya bahawa proses apoptotik bermula pada 
peringkat yang sangat awal bagi gabungan virus dan „hyperthermia‟  berbanding 
dengan virus sahaja. Ini dibuktikan melalui tenaga kinetik yang paling tinggi didapati 
dalam caspase 3 manakala virus sahaja yang tertinggi dalam caspase 8. 
Kesimpulannya, induksi Hsp70 oleh perlakuan „hyperthermia‟  meningkatkan  
replikasi Ad5-p53-DsRed Monomer N1 dan „oncolysis‟ dalam sel MDA-MB 231 
dan MCF-7 melalui proses apoptotik. Selain itu, NBD bagi Hsp70 mempunyai 
interaksi yang terbaik dengan PNLVP motif pada 42°C. Oleh itu, penggabungan 
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1.1 Background of study 
Currently, breast cancer is the fifth leading cause of cancer-related deaths for 
both men and women in the worldwide, accounting for 521,000 deaths in 2012 
(World Health Organization, 2014).  In Malaysia, breast cancer is the most common 
cancer where 1 in 19 Malaysian women will be diagnosed with breast cancer by the 
age of 85 (National Cancer Registry of Malaysia, 2014).  Most cases occur during 
age 45-55.  It is the most common cancer diagnosed in women (25.2% of all new 
cases in women) (World Health Organization, 2014).  In addition, 10-15% of women 
treated for early breast cancer suffer a local recurrence (locally recurrent breast 
cancer, LRBC) within 10 years (Clemons et al., 2001). Local failure causes 
significant physical and psychosocial morbidity (van der Zee et al., 1999), and the 
majority of these patients die of their disease within 5 years of recurrence (Clemons 
et al., 2001).  This is due to the poor prognosis such as lack of specific symptoms in 
the early stage of disease leading to delays in diagnosis, the aggressive nature of 
disease, as evidenced by the high rate of local spread and/or distant metastasis at the 
time of diagnosis, diagnosis techniques that lack sufficient sensitivity and specificity 
to support screening for breast cancer. At present, the cancer treatment by 
chemotherapeutic agents, surgery and radiation has not been fully effective against 
the high incidence or low survival rate of breast cancer. Furthermore, these 
treatments cause negative side effects such as liver failure, cardiomyopathy and an 
increased risk of developing other types of cancer (Hawkins and Hermiston, 2001). 
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Thus, the development of a new therapeutic approach to breast cancer remains one of 
the most challenging area in cancer research.  
Gene therapy is a new therapeutic approach for breast cancer.  It specifically 
targets the tumour cells including metastatic cells in the body (Abaan and Criss, 
2002).  It has been shown to be effective with different types of diseases (Rubanyi, 
2001).  Therefore, it may be applicable for the treatment of breast cancer patients. 
Oncolytic adenoviruses are a class of promising anti-cancer agents, which are 
engineered to infect, replicate within, and lyses cancer cells (Yamamoto and Curiel, 
2009).  However, these agents alone failed to generate sustained clinical responses or 
to cause complete tumour regressions.  This is because heterogeneity or indeed lack 
of expression of receptors (coxsackie adenovirus receptor, CAR) and co-receptors 
(integrin αvβ3 and αvβ5 classes) in tumours can be implicated in the poor efficiency of 
infectivity by adenovirus (Bauerschmitz et al., 2002; Kanerva and Hemmiki, 2004).  
In addition, many tumour cells fail to support adenovirus replication because of its 
replication deficiency.  Thus, combination treatment is needed to improve the clinical 
outcome in breast cancer treatment.  
Hyperthermia has been explored intensively to treat cancer patients.  It is 
used to raise the temperature of a region of the body affected by cancer up to 41.5-
43°C with minimal or no damaging healthy tissues (van der Zee, 2002).  Several 
investigators suggested that hyperthermia might enhance viral replication, 
particularly in tumour cells (Thorne et al., 2005).  Heat shock protein (Hsp) is the 
key player for the hyperthermia hypothesis.  Glotzer et al. (2000) described that Hsp 
may play a vital role in the adenovirus life cycle because genome replication, 
synthesis of protein and virion assembly which are vital for viral replication, is 
dependent on the host cell.  Hsp especially Hsp70 is the main responsible for import 
and colocalizes viral proteins in the nucleus with E1A gene products of adenovirus 
(Kao et al., 2005).  Furthermore, Wickner et al. (1992) documented that bacterial 
DNAJ and DNAK, which are important for bacteriophage DNA replication, may 
depend on Hsp70 induction.  Hsp40 and Hsp70 induction promotes production of 
viral proteins for avian adenovirus CELO (Glotzer et al., 2000).  
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Hyperthermia induces transgene expression, represents a promising strategy 
using the combination of hyperthermia with virotherapy (Huang et al., 2000; Lohr et 
al., 2000; Walther and Stein, 2009).  Nevertheless, there are only few studies on this 
combination treatment against cancer.  Based on Eisenberg et al. (2010) study, it has 
been demonstrated that the combination of hyperthermia and NV1066 (a 
recombinant herpes simplex virus-1) infection significantly increased the pancreatic 
cancer cell kill to approximately 80% without damaging normal cells.  Therefore, 
adenovirus in combination with hyperthermia can be a potential treatment for breast 
cancer patients.  
1.2 Problem statement of research  
There have been numerous strategies attempted in the past to treat breast 
cancers with limited success. One of the latest approaches is adenovirus gene 
therapy. Although the oncolytic adenoviruses are promising anti-cancer agents, 
clinical studies demonstrated that viral therapy alone failed to produce sustained 
clinical responses or to destroy tumour completely. This is due to lack of expression 
of coxsackie adenovirus receptor and co-receptors in tumour cells which is crucial 
for adenovirus infection. Therefore, tumour cells hinder replication of adenovirus.  
While the treatment effects of hyperthermia as a single agent are limited, its 
ability to potentiate the effects of standard chemo-radiotherapies has generated 
lasting interest. Yet, combination of hyperthermia with either chemotherapy, 
radiotherapy or both, led to improved clinical outcome in treatment of breast cancer; 
they have been shown potential side effects, such as impotence or incontinence that 
can greatly impair life quality (van der Zee, 2002). Thus, a novel approach of 
combining gene therapy and hyperthermia will be explored to be a new way to treat 
breast cancer cells. 
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1.3 Hypotheses of study  
The hypotheses of this study are:  
1. Can coupling of hyperthermia and Ad5-p53-DsRed Monomer N1 
enhances killing of breast cancer cells (MCF-7 and MDA-MB 231)? 
2. Can heat treatment induced Hsp70 and p53 expression in breast 
cancer cells? 
3. Does the combination of hyperthermia and Ad5-p53-DsRed Monomer 
N1 involved in apoptosis pathway? 
4. Is there any protein interaction between nucleotide binding domain 
(NBD) of Hsp70 and E1A 32 kDa motif (PNLVP)? 
5. Is there any protein interaction between NBD of Hsp70 and p53 motif 
(SCMGGMNR)? 
1.4 Objectives of study  
The objectives of this study are:  
1. To determine the cytotoxic effects of hyperthermia alone, Ad5-p53- 
DsRed Monomer N1 alone and combination of hyperthermia and 
Ad5-p53-DsRed Monomer N1 on breast cancer lines (MCF-7 and 
MDA-MB 231). 
2. To determine the expression of Hsp70 in breast cancer cells after 
treated with Ad5-p53-DsRed Monomer N1 in combination with 
hyperthermia. 
3. To determine p53 expression in breast cancer cells for combination 
treatment of Ad5-p53-DsRed Monomer N1 and hyperthermia. 
4. To determine the possible pathway involved in apoptosis for MDA-
MB 231 and MCF-7 cells after treated with the combination of Ad5-
p53-DsRed Monomer N1 and hyperthermia. 
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5. To identify novel protein interaction between NBD of Hsp70 and E1A 
32 kDa of human adenovirus serotype 5 motif (PNLVP). 
6. To identify novel protein interaction between NBD of Hsp70 and p53 
motif (SCMGGMNR). 
1.5 Scope of research   
This study involves construction of recombinant adenovirus, cytotoxicity, 
quantitation of viral replication, protein expression, protein modeling, molecular 
dynamic (MD) simulation of protein and protein-protein docking.  Firstly, Ad5-p53 
will be constructed by cloning p53 gene into defective recombinant adenovirus 
vector containing red fluorescent protein (DsRed Monomer N1).  Then, Ad5-p53-
DsRed Monomer N1 (multiplicity of infection of 100 PFU per cell, MOI of 100) will 
be infected with MCF-7 and MDA-MB 231 breast cancer cells.  Cells will be treated 
at 42°C for 2 hours prior to viral treatment.  The formation of viral plaques and cell 
survival (MTT assay) will be measured. After that, Hsp70 and p53 protein 
expression will be quantitated using ELISA assay. Activated-Caspase 3/7, 8 and 9 
will also be performed to study the apoptotic pathway of cancer cells.  Besides that, 
the novel protein interaction between NBD of Hsp70 and E1A 32 kDa of human Ad5 
motif (PNLVP); and NBD and p53 motif (SCMGGMNR) will be investigated 
through bioinformatics tools such as Gromacs version 4.6.3 and Autodock version 
4.2. 
1.6 Significance of study  
The beneficial outcome of this study is that the novel therapeutic regimen, 
combining the effects of recombinant adenovirus (Ad5-p53-DsRed Monomer N1) 
and hyperthermia (42ºC for 2 hours) can be explored as a potential breast cancer 
treatment.  Furthermore, this combination treatment could be a useful application to 
develop adenovirus-based gene transfer to breast cancer cells.  In spite of that, 
understanding the stability of Hsp70; the preferred sites of interaction between 
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Hsp70 and E1A 32 kDa of human Ad5; and the binding affinity and stability Hsp70-
p53 motif complex structure through bioinformatics tools is the key to design 






Abaan, D., and Criss, W.E. (2002). Gene therapy in human breast cancer. Turk. J. 
Med. Sci. 32, 283-291. 
Abavaya, K., Myers, M.P., Murphy, S.P., and Morimoto, R.I. (1992). The human 
heat shock protein hsp70 interacts with HSF, the transcription factor that 
regulates heat shock gene expression. Genes Dev. 6, 1153-1164. 
Acehan, D., Jiang, X., Morgan, D.G., Heuser, J.E., Wang, X., and Akey, C.W. 
(2002). Three-dimensional structure of the apoptosome: Implications for 
assembly, procaspase-9 binding, and activation. Mol. Cell. 9, 423-432. 
Ala-aho, R., Grenman, R., Seth, P., and Kahari, V.M. (2002). Adenoviral delivery of 
p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous 
carcinoma cells. Oncogene. 21, 1187-1195. 
Al-Lazikani, B., Jung, J., Xiang, Z., and Honig, B. (2001). Protein structure 
prediction. Curr. Opin. Chem. Biol. 5, 51-56. 
Alley, M.C., Scudiero, D.A., Monks, A., Hursey, M.L., Czerwinski, M.J., Fine, D.L., 
Abbott, B.J., Mayo, J.G., Shoemaker, R.H., and Boyd, M.R. (1988). 
Feasibility of drug screening with panels of human tumor cell lines using a 
microculture tetrazolium assay. Cancer Res. 48, 589-601. 
American Cancer Society (ACS). (2009). Hyperthermia. Updated July 17, 2009. 
Available online: 
http://www.cancer.org/docroot/ETO/content/ETO_1_2x_Hyperthermia.asp 
(accessed on 1 May 2014) 
American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Georgia, 2014. 
Andersson, S., Davis, D. L., Dahlback, H., Jornvall, H., and Russell, D. W. (1989). 
Cloning, structure, and expression of the mitochondrial cytochrome P-450 




Ansieau, S., and Leutz, A. (2002). The conserved Mynd domain of BS69 binds 
cellular and oncoviral proteins through a common PXLXP motif. J. Biol. 
Chem. 277, 4906-4910. 
Anthony, M.B., Paul, S., Duc, N., Fei-Fei, L., and Henry, J.K. (2003). Heat-directed 
suicide gene therapy for breast cancer. Cancer Gene Ther. 10, 294-301. 
Antonie, G., van der Heijden, Cornelius, F.J., Jansen, Verhaegh, G., Michael, A., 
O’Donnell, Jack, S., and Alfred, W.J. (2004). The effect of hyperthermia on 
mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. 
Eur. Urol. 46, 670-674. 
Arya, R., Mallik, M., and Lakhotia, S.C. (2007). Heat shock genes - integrating cell 
survival and death. J. Biosci. 32(3), 595-610. 
Appenheimer, M.M., Chen, Q., Girard, R.A., Wang, W.C., and Evans, S.S. (2005). 
Impact of fever-range thermal stress on lymphocyte-endothelial adhesion and 
lymphocyte trafficking. Immunol. Invest. 34(3), 295-323. 
Babich, A., Feldman, L.T., Nevins, J.R., Darnell, J.E., and Weinberger, C. (1983). 
Effect of adenovirus on metabolism of specific host mRNAs: transport 
control and specific translational discrimination. Mol. Cell Biol. 3, 1212-
1221. 
Bai, M., Harfe, B., and Freimuth, P. (1993). Mutations that alter an Arg-Gly-Asp 
(RGD) sequence in the sequence in the adenovirus type 2 penton base protein 
abolish its cell-rounding activity and delay virus reproduction in flat cells. J. 
Virol. 67, 5198-5205. 
Bao, T., and Rudek, M.A. (2011). The clinical pharmacology of anastrozole. Eur. 
Oncol. & Haematol. 7(2), 106-108. 
Bauerschmitz, G.J., Barker, S.D., and Hemminki, A. (2002). Adenoviral gene 
therapy for cancer: from vectors to target and replication competent agents. 
Int. J. Oncol. 21, 1161-1174. 
Bell, S., Klein, C., Muller, L., Hansen, S., and Buchner, J. (2002). p53 contains large 
unstructured regions in its native state. J. Mol. Biol. 322(5), 917-927. 
Bennett, M., Macdonald, K., Chan, S.W., Luzio, J.P., Simari, R., and Weissberg P. 
(1998). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated 
apoptosis. Sci. 282, 290-293. 
231 
 
Biro, J.C., Benyo, B., Sansom, C., Szlavecz, A., Fordos, G., and Micsik, T., Benyo, 
Z. (2003). A common periodic table of codons and amino acids. Biochem. 
Biophys. Res. Commun. 306, 408-415. 
Boatright, K.M., Deis, C., Denault, J.B., Sutherlin, D.P., and Salvesen, G.S. (2004). 
Activation of caspases-8 and -10 by FLIPL. Biochem. J. 382, 651-657. 
Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein, B., and Schaffner, 
W. (1985). A very strong enhancer is located upstream of an immediate early 
gene of human cytomegalovirus. Cell. 41, 521-530. 
Breast Cancer. (2015). Available online: 
http://en.wikipedia.org/wiki/Breast_cancer (accessed on 27st January 2015). 
Breast Cancer Treatment (PDQ®). (2014). Available online: 
http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page1/AllPa
ges (accessed on 1st May 2014). 
Buchberger, A., Schroder, H., Buttner, M., Valencia, A., and Bukau, B. (1994). A 
conserved loop in the ATPase domain of the DnaK chaperone is essential for 
stable binding of GrpE. Nat. Struct. Biol. 1, 95-101. 
Buller, R.E., Runnebaum, I.B., and Karlan, B.Y. (2002). A phase I/II trial of rAd/p53 
(SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene 
Ther. 9, 553-566. 
Burgoyne, N.J., and Jackson, R.M. (2006). Predicting protein interaction sites: 
binding hot-spots in protein-protein and protein-ligand interfaces. 
Bioinformatics. 22, 1335-1342. 
Calderwood, S.K., Theriault, J.R., and Gong, J. (2005). How is the immune response 
affected by hyperthermia and heat shock proteins? Int. J. Hyperthermia. 
21(8), 713-716. 
Campbell, K.S., Mullane, K.P., Aksoy, I.A., Stubdal, H., Zalvide, J., Pipas, J.M., 
Silver, P.A., Roberts, T.M., Schaffhausen, B.S., and DeCaprio, J.A. (1997). 
DnaJ/hsp40 chaperone domain of SV40 large T antigen promotes efficient 
viral replication. Genes Dev. 11, 1098-1110. 
Carbone, D.P., Adak, S., and Schiller, J. (2003). Adenovirus p53 administered by 
bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma 




Cavalier, E., Chakravarti , D., and  Guttenplan, J. (2006). Catechol estrogen quinones 
as initiators of breast and other human cancers: implications for biomarkers 
of susceptibility and cancer prevention. Biochim. Biophys. Acta. 1766(1), 63-
78. 
Center for Cancer Systems Biology (CCSB) hORFeome V5.1. (2003). Available 
online: http://horfdb.dfci.harvard.edu/hv5/ (accessed on 5th March 2011). 
Chen, Y., De Weese, T., and Dilley, J. (2001). CV706, a prostate cancerspecific 
adenovirus variant, in combination with radiotherapy produces synergistic 
antitumor efficacy without increasing toxicity. Cancer Res. 61, 5453-5460. 
Chirico, W.J., Waters, M.G., and Blobel, G. (1988). 70K heat shock related proteins 
stimulate protein translocation into microsomes. Nature, 332, 805-810. 
Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., 
Schuler, M., and Green, D.R. (2004). Direct activation of Bax by p53 
mediates mitochondrial membrane permeabilization and apoptosis. Sci.  303, 
1010-1014. 
Chou, J.J., Li, H., Salvesen, G.S., Yuan, J., and Wagner, G. (1999). Solution 
structure of BID, an intracellular amplifier of apoptotic signaling. Cell. 96, 
615-624. 
Chung, C.T., Niemela, S.L., and Miller, R.H. (1989). One step preparation of 
competent Escherichia coli: transformation and storage of bacterial cells in 
the same solution. Pro. Natl. Acad. Sci. USA. 86, 2172-2175. 
Ciocca, D.R., Fanelli, M.A., Cuello-Carrion, F.D., and Castro, G.N. (2010). Heat 
shock proteins in prostate cancer: from tumorigenesis to the clinic. Int. J. 
Hyperthermia. 26(8), 737-747. 
Clayman, G.L., el-Naggar, A.K., and Lippman, S.M. (1998). Adenovirus-mediated 
p53 gene transfer in patients with advanced recurrent head and neck 
squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232. 
Clemons, M., Danson, S., and Hamilton, T. (2001). Locoregionally recurrent breast 
cancer: incidence, risk factors and survival. Cancer Treat Rev. 27, 67-82. 
Clemons, M., Hamilton, T., and Goss, P. (2001). Does treatment at the time of 




Cline, J., Braman, J.C., and Hogrefe, H.H. (1996). PCR fidelity of Pfu DNA 
polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 
24(18), 3546. 
Clontech Laboratories, A Takara Bio Company. pDsRed Monomer N1 vector 
information. (2006)  
Colovos, C., and Yeates, T.O. (1993). Verification of protein structures: patterns of 
non-bonded atomic interactions. Protein Sci. 2, 1511-1519. 
Costantini, S., Colonna, G., and Facchiano, A.M. (2008). ESBRI: a web server for 
evaluating salt bridges in proteins. Bioinformation. 3, 137-138. 
Cristofanilli, M., Khrisnamurthy, S., and Guerra, L. (2003). Ad5CMV-p53 combined 
with docetaxel (T) and doxorubicin (D) as induction chemotherapy (IC) for 
patients with locally advanced breast cancer (LABC): preliminary report of 
safety and efficacy. Proc. Am. Soc. Clin. Oncol. 22, 967. 
Cross, D., and Burmester, J.K. (2006). Gene Therapy for Cancer Treatment: Past, 
Present and Future. J. Clin. Med. Res.  4(3), 218-227. 
Dahl, O., Borkamo, E.D., and Fluge, O. (2008). Current status of antivascular 
therapy and targeted treatment in the clinic. Int. J. Hyperthermia. 24(1), 97-
110. 
David, L., Huber, W., Granoskaia, M., Toedling, J., Palm, C.J.Bofkin, L., Jones, T., 
David, R.W., and Steinmetz, M. (2006). A high resolution map of 
transcription in yeast genome. Pro. Natl. Acad. Sci. USA. 103(14), 5320-
5325. 
Dayanc, B.E., Beachy, S.H., Ostberg, J.R., and Repasky, E.A. (2008). Dissecting the 
role of hyperthermia in natural killer cell mediated anti-tumor responses. Int. 
J. Hyperthermia. 24(1), 41-56. 
Dieing, A., Ahlers, O., Hildebrandt, B., Kerner, T., Tamm, I., Possinger, K., and 
Wust, P. (2007). The effect of induced hyperthermia on the immune system. 
Prog. Brain Res. 162, 137-152. 
Dieffenbach, Lowe, T.M., and Dveksler, G.S. (1993). General concepts for PCR 
primer design. Genome Res. 3, 30-37. 
Delano, W.L. The PyMOL Molecular Graphics System. (2001). Available online: 
http://www.pymol.org (accessed on 10th September 2013) 
234 
 
Dennis, B., Ponciano, J.M., Lele, S.R., Taper, M.L., and Staples, D.F. (2006). 
Estimating density dependence, process noise, and observation error. Ecol. 
Monogr. 76(3), 323-341. 
Dewhirst, M.W., Vujaskovic, Z., Jones, E., and Thrall, D. (2005). Re-setting the 
biologic rationale for thermal therapy. Int. J. Hyperthermia. 21(8), 779-790. 
Diller, L., Kassel, Y., Nelson, C.E., Gryka, M.A., Litwak, G., Gebhardt, M., Bressac, 
B., Ozturk, M., Baker, S.J., Vogelstein, B., and Friend, S. (1990). p53 
functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol. 10, 
5772-5781. 
Dunning, A.M., Healey, C.S., Pharoah, P.D., Teare, M.D., Ponder, B.A., and Easton, 
D.F. (1999). A systematic review of genetic polymorphisms and breast cancer 
risk". Cancer Epidemiol. Biomarkers & Prev. 8(10), 843-854. 
Eisenberg, D., Luthy, R., and Bowie, J.U. (1997). VERIFY3D: assessment of protein 
models with three-dimensional profiles. Methods Enzymol. 277, 396-404. 
Eisenberg, D.P., Carpenter, S.G., Adusumilli, P.S., Chan, M.K., Hendershott, K.J., 
Yu, Z., and Fong, Y. (2010). Hyperthermia potentiates oncolytic herpes viral 
killing of pancreatic cancer through a heat shock protein pathway. Surgery. 
148(2), 325-334. 
Ellis, R.J., and van der Vies, S.M. (1991). Molecular chaperones. Ann. Rev. Biochem. 
60, 321-347. 
Fields, B.N., Knipe, D.M., and Howley, P.M. (1996). Fields virology, Lippincott-
Raven Philadelphia. 
Fiser, A., and Sali, A. (2003). Modeller: Generation and refinement of homology-
based protein structure models. Methods Enzymol. 374, 461-491. 
Flaherty, K.M., Wilbanks, S.M., DeLuca-Flaherty, C., and McKay, D.B. (1994). 
Structural basis of the 70 kilodalton heat shock cognate protein ATP 
hydrolytic activity. J. Biol. Chem. 269, 12899-12907. 
Fourie, A.M., Hupp, T.R., Lane, D.P., Sang, B.C., Barbosa, M.S., and Sambrook, 
J.F. (1997). HSP70 binding sites in the tumor suppressor protein p53. J. Biol. 






Franckena, M., Lutgen,s L.C., Koper, P.C., Kleynen, C.E., van der Steen-Banasik, 
E.M., Jobsen, J.J., Leer, J.W., Creutzberg, C.L., Dielwart, M.F., van Norden, 
Y., Canters, R.A., van Rhoon, G.C., and van der Zee, J. (2009). Radiotherapy 
and hyperthermia for treatment of primary locally advanced cervix cancer: 
results in 378 patients. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 242-250. 
Franckena, M., and van der Zee, J. (2010). Use of combined radiation and 
hyperthermia for gynecological cancer. Curr. Opin. Obstet. Gynecol. 22(1), 
9-14. 
Freeman, B.C., and Yamamoto, K.R. (2002). Disassembly of transcriptional 
regulatory complexes by molecular chaperones. Sci.  296, 2232-2235. 
Frey, B.M., Hackett, N.R., and Bergelson, J.M. (1998). High-efficiency gene transfer 
into ex vivo expanded human hematopoietic progenitors and precursor cells 
by adenovirus vectors. Blood. 91, 2781-2792. 
Fukaoa, H., Ikedaa, M., Ichikawaa, T., Inufusa, H., Okada, K., Ueshima, S., and 
Matsuo, O. (2000). Effect of hyperthermia on the viability and the fibrinolytic 
potential of human cancer cell lines. Clin. Chim. Acta. 296, 17-33. 
Gabai, V.L., and Kabakov A.E. (1993). Tumor cell resistance to energy deprivation 
and hyperthermia can be determined by the actin skeleton stability. Cancer 
Lett, 70(2), 25-31.  
Gaber, M.H., Wu, N.Z., Hong, K., Huan, S.K., Dewhirst, M.W., and 
Papahadjopoulos, D. (1996). Thermosensitive liposomes: extravasation and 
release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. 
Biol. Phys. 36(5), 1177-1187. 
Gallimore, P.H., and Turnell, A.S. (2001). Adenovirus E1A: remodelling the host 
cell, a life or death experience. Oncogene. 20, 7824-7835. 
Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M.R., Appel, R.D., 
and Bairoch, A. (2005). Protein identification and analysis tools on the 
ExPASy server. In Walker, J.M. (Ed.) In The Proteomics Protocols 
Handbook. (pp. 571-607). Totowa, NJ, USA: Humana Press. 
George Priya Doss, C., and Nagasundaram, N. (2012). Investigating the structural 
impacts of I64T and P311S mutations in APE1-DNA complex: A Molecular 
Dynamics Approach. PLoS One. 7, 1-11. 
236 
 
Geourjon, C., and Deleage, G. (1995). SOPMA: Significant improvements in protein 
secondary structure prediction by consensus prediction from multiple 
alignments. Comput. Appl. Biosci. 11, 681-684. 
Gething, M.J., and Sambrook, J. (1992). Protein folding in the cell. Nature. 355, 33-
45. 
Gerner, E.W., Hersh, E.M., Pennington, M., Tsang, T.C., Harris, D., Vasanwala, F., 
and Brailey, J. (2000). Heat-inducible vectors for use in gene therapy. Int. J. 
Hyperthermia. 16, 171-181. 
Giacca, A.J., and Kastan, M.B. (1998). The complexity of p53 modulation: Emerging 
patterns from divergent signals. Genes Dev. 12, 2973-2983. 
Gilis, D., and Rooman, M. (1997). Predicting protein stability changes upon mutation 
using database-derived potentials: solvent accessibility determines the 
importance of local versus non-local interactions along the sequence. J. Mol. 
Biol. 272, 276-290. 
Glotzer, J.B., Saltik, M., Chiocca, S., Michou, A.I., Moseley, P., and Cotton, M. 
(2000). Activation of heat-shock response by an adenovirus is essential for 
virus replication. Nature. 407, 207-211. 
Goodrum, F. D., and Ornelles, D. A. (1998). p53 status does not determine outcome 
of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-
9490. 
Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and 
Giacca, A.J. (1996). Hypoxia-mediated selection of cells with diminished 
apoptotic potential in solid tumours. Nature. 379, 88-91. 
Gundampati, R.K., Chikati, R., Kumari, M., Sharma, A., Pratyush, D.D., 
Jagannadham, M.V., Kumar, C.S., and Das, M.D. (2012). Protein-protein 
docking on molecular models of Aspergillus niger RNase and human actin: 
Novel target for anticancer therapeutics. J. Mol. Model. 18, 653-662. 
Hainaut, P., Butcher, S., and Milner, J. (1995). Temperature sensitivity for 
conformation is an intrinsic property of wild-type p53. Br. J. Cancer. 71, 
227-231. 
Han, J.S., Storck, C.W., and Wachsberger, P.R. (2002). Acute extracellular 
acidification increases nuclear associated protein levels in human melanoma 
cells during 42 degrees C hyperthermia and enhances cell killing. Int. J. 
Hyperthermia. 18, 404-415. 
237 
 
Hatebour, G., Gennissen, A., Ramos, Y.F., Kerkhoven, R.M., Sonntag-Buck, V., 
Stunnenberg, H.G., and Bernards, R. (1995). BS69, a novel adenovirus E1A-
associated protein that inhibits E1A transactivation. EMBO J. 14, 3159-3169. 
Hawkins, L.K., and Hermiston, T. (2001). Gene delivery from the E3 region of 
replicating human adenovirus: evaluation of the E3B region. Gene Ther. 8, 
1142-1148. 
Hightower, L.E. (1991). Heat shock, stress proteins, chaperones, and proteotoxicity. 
Cell. 66, 191-197. 
Hitt, M. M., Parks, R. J., and Graham, F. L. (1999). Structure and Genetic 
Organization of Adenovirus Vectors. In The Development of Human Gene 
Therapy, T. Friedmann, ed. (Cold Spring Harbor, NY: Cold Spring Harbor 
Laboratory Press), pp. 61-86. 
Huan, Q., Hu, J.K, Lohr, F., Zhang, L., Braun, R., Lanzen, J., Little, J.B., Dewhirst, 
M.W., and Li, C.Y. (2000). Heat-induced gene expression as a novel targeted 
cancer gene therapy strategy. Cancer Res. 60(13), 3435-3439. 
Huang, Q., Hu, J.K., Lohr, F., Zhang, L., Braun, R., Lanzen, J., Little, J.B., Dewhirst, 
M.W., and Li, C.Y. (2000). Heat-induced gene expression as a novel targeted 
cancer gene therapy strategy. Cancer Res. 60(13), 3435-3439. 
Hurlin, P.J., Steingrimsson, E., Copeland, N.G., Jenkins, N.A., and Eisenman, R.N. 
(1999). Mga, a dual-specificity transcription factor that interacts with Max 
and contains a T-domain DNA-binding motif. EMBO J. 18, 7019-7028. 
Imperiale, M.J., Kao, H.T., Feldman, L.T., Nevins, J.R., and Strickland, S. (1984). 
Common control of the heat shock gene and early adenovirus genes: evidence 
for a cellular E1A-like activity. Mol. Cell Biol. 4, 867-874. 
Integrated DNA Technologies (Oligo Analyzer 3.1). Available online: 
https://sg.idtdna.com/calc/analyzer (accessed on 5th March 2011). 
Iosub-Amir, A., and Friedler, A. (2014). Protein–protein interactions of ASPP2: an 
emerging therapeutic target. Med. Chem. Commun. 5, 1435-1443. 
Issels, R.D. (2008). Hyperthermia adds to chemotherapy. Eur. J. Cancer. 44, 2546-
2554. 
Issels, R.D. (2006). High-risk soft tissue sarcoma: clinical trial and hyperthermia 
combined chemotherapy. Int. J. Hyperthermia. 22(3), 235-239. 
Ito, A., Kugaa, Y., Hondaa, H., Kikkawab, H., Horiucib, A., Watanabeb, Y., and 
Kobayashia, T. (2004). Magnetite nanoparticle-loaded anti-HER2 
238 
 
immunoliposomes for combination of antibody therapy with hyperthermia. 
Cancer Lett. 212, 167-175. 
Jahanzeb, M. (2008). Adjuvant trastuzumab therapy for HER2-positive breast cancer. 
Clin. Breast Cancer. 8 (4), 324-333. 
James, D.W., Tania, A.B., Stephen, P.B., Alexander, G., Michael, L., and Richard, L. 
(2004). Molecular Biology of the Gene. Pearson Benjamin Cummings, Inc. 
5th ed, pp. 648-655. 
James, S.J., Melyk, S., Cleves, M.A., Halsted, C.H., Wong, D.H., Culter, P., Bock, 
K., Boris, M., Bradstreet, J.J., Baker, S.M., and Gaylor, D.W. (2006). 
Metabolic endophenotype and related genotypes are associated with oxidative 
stress in children with autism. Am. J. Med. Genet. B Neurophychiatr. Genet. 
141B, 947-956. 
Johnson, K.T., Rodicker, F., and Heise, K. (2005). Adenoviral p53 gene transfer 
inhibits human Tenon's capsule fibroblast proliferation. Br. J. Ophthalmol. 
89, 508-512. 
Kabsch, W., Mannherz, H.G., Suck, D., Pai, E.F., and Holmes, K.C. (1990). Atomic 
structure of the actin: DNAse I complex. Nature. 347, 37-44. 
Kampinga, H.H. (2006). Cell biological effects of hyperthermia alone or combined 
with radiation or drugs: a short introduction to newcomers in the field. Int. J. 
Hyperthermia. 22(3), 191-196. 
Kampinga, H.H., Hageman, J., Vos, M.J., Kubota, H., Tanguay, R.M., Bruford, E.A., 
Cheetham, M.E., Chen, B., and Hightower, L.E. (2009). Guidelines for the 
nomenclature of the human heat shock proteins. Cell Stress Chaperones. 14, 
105-111. 
Kanerva, A., and Hemminki, A. (2004). Modified adenoviruses for cancer gene 
therapy. Int. J. Cancer. 110, 475-480. 
Kao, H.T., Capasso, O., Heintz, N., and Nevins, J.R. (2005). Cell cycle control of the 
human HSP70 gene: Implications for the role of a cellular E1A-like function. 
Mol. Cell. Biol. 5, 628-633. 
Kiang, J. G., and Tsokos, G. C. (1998). Heat shock protein 70 kDa: molecular 
biology, biochemistry, and physiology. Pharmacol. Ther. 80, 183-201. 
Kibbe, W.A. (2007). OligoCalc: an online oligonucleotide properties calculator. 
Nucleic Acids Res. 35(2): W43-W46. 
239 
 
Krishna, R., and Mayer, L.D. (2000). Multidrug resistance (MDR) in cancer. 
Mechanisms, reversal using modulators of MDR and the role of MDR 
modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. 
Pharm. Sci. 11, 265-283. 
Kruidering, M., and Evan, G.I. (2000). Caspase-8 in apoptosis: the beginning of ‘‘the 
end’’? IUBMB Life. 50, 85-90. 
Kuball, J., Wen, S.F., and Leissner, J. (2002). Successful adenovirus-mediated wild-
type p53 gene transfer in patients with bladder cancer by intravesical vector 
instillation. J. Clin. Oncol. 20, 957-965. 
Kumar, S., Tsai, C.J., Ma, B., and Nussinov, R. (2000). Contribution of salt bridges 
toward protein thermo stability. J. Biomol. Struct. Dyn. 1, 79-86. 
Kumar, S., and Nussinov, R. (2002). Relationship between ion pair geometries and 
electrostatic strengths in proteins. Biophys. J. 83, 1595-1612. 
Kumar, S., and Nussinov, R. (2009). Salt bridge stability in monomeric proteins. J. 
Mol. Biol. 293, 1241-1255. 
Kumar, D. P., Vorvis, C., Sarbeng, E. B., Cabra Ledesma, V. C., Willis, J. E., and 
Liu, Q. (2011). The four hydrophobic residues on the Hsp70 inter-domain 
linker have two distinct roles. J. Mol. Biol. 411, 1099-1113. 
Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., and Moreau, J. (1996). 
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor 
transactivation domain. Sci. 274, 948-953. 
Kuntal, B.K., Aparoy, P., and Reddanna, P. (2010). EasyModeller: A graphical 
interface to MODELLER. BMC Res. Notes. 3, 226. 
Laible, D.B.M. (ed). Selection and production of recombinant binders for use in 
microarrays: diploma thesis. GRIN Verlag. 31-32; 2009. 
Laurie, A.T., and Jackson, R.M. (2005). Q-SiteFinder: an energy-based method for 
the prediction of protein-ligand binding sites. Bioinformatics. 21, 1908-1916. 
Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. (1993). 
PROCHECK: a program to check the stereo-chemical quality of protein 
structures. J. Appl. Cryst. 26, 283-291. 
Li, Y., Li, J., Zhang, S.T., Wang, L.J., Zhang, Z., Gao, N., Zhang, Y.Y., and Chen, 
Q.M. (2009). In vitro and clinical studies of gene therapy with recombinant 




Li, Y., Dowbenko, D., and Lasky, L. A. (2002). AKT/PKB phosphorylation of 
p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell 
survival. J. Biol. Chem. 277, 11352-11362. 
Li, H.L., Zhu, H., and Xu, C.J. (1998). Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell. 94, 491-501. 
Lindner, L.H., and Issels, R.D. (2011). Hyperthermia in soft tissue sarcoma. Curr. 
Treat Options Oncol. 12(1), 12-20. 
Liu, X., Kim, C.N., Yang, J., Jemmerson, R., and Wang, X. (1996). Induction of 
apoptotic program in cell-free extracts: Requirement for dATP and 
cytochrome c. Cell. 86, 147-157. 
Liu, J.S., Kuo, S.R., Makhov, A.M., Cyr, D.M., Griffith, J.D., Broker, T.R., and 
Chow, L.T. (1998). Human Hsp70 and Hsp40 chaperone proteins facilitate 
human papillomavirus-11 E1 protein binding to the origin and stimulate cell-
free DNA replication. J.Biol.Chem. 273, 30704-30712. 
Liu, Q., and Hendrickson, W. A. (2007). Insights into Hsp70 chaperone activity from 
a crystal structure of the yeast Hsp110. Sse1 Cell. 131, 106-120. 
Lo, H.W., Wang, S.C., and Hung, M.C. (2006). Novel signaling pathways in breast 
cancer. In Piccart, M., Wood, W.C., Hung, M.C., Solin, L.J., and Cardoso, F. 
(Ed.). Breast Cancer Management and Molecular Medicine: Towards 
Tailored Approaches (pp. 832-839). Berlin: Springer-Verlag. 
Lohr, F., Hu, K., Huan, Q., Zhang, L., Samulski, T.V., Dewhirst, M.W., and Li, C.Y. 
(2000). Enhancement of radiotherapy by hyperthermia-regulated gene 
therapy. Int. J. Radiat. Oncol. Biol. Phys. 48(5), 1513-1518. 
Lou, J., Xu, F., Merkel, K., and Manske, P. (1999). Gene therapy: adenovirus-
mediated human bone morphogenetic protein-2 gene transfer induces 
mesenchymal progenitor cell proliferation and differentiation in vitro and 
bone formation in vivo. J. Orthop. Res. 17, 43-50. 
Lu, X., and Lane, D.P. (1993). Differential induction of transcriptionally active p53 
following UV or ionizing radiation: Defects in chromosome instability 
syndromes? Cell. 75, 765-778. 
Macarron, R. (2006). Critical review of the role of HTS in drug discovery. Drug Dis. 
Today. 11, 277-279. 
Madhusudhan, M.S., Marc., Marti-Renom, A., Eswar, N., John, B., Pieper, U., 
Karchin, R., Shen, M.Y., and Sali, A. (2005). Comparative Protein Structure 
241 
 
Modeling. In Walker, J.M (Ed.) The Proteomics Protocols Handbook (pp. 
831-860). NJ: Humana Press Inc. 
Macejak, D.G., and Luftig, R.B. (1991). Stabilization of actin filaments at early 
times after adenovirus infection and in heat-shocked cells. Virus Res. 19, 31-
45. 
Macejak, D.G., and Luftig, R.B. (1991). Association of HSP70 with the adenovirus 
type 5 fiber protein in infected HEp-2 cells. Virol. 180, 120-125. 
Marder, J., Elylath, U., Moskovitz, E., and Sharir, R. (1990). The effect of heat 
exposure on blood chemistry of the hyperthermic rabbit. Comput. Biochem. 
Physiol. 97, 245-247. 
Maluta, S., Dall'Oglio, S., and Romano, M. (2007). Conformal radiotherapy plus 
local hyperthermia in patients affected by locally advanced high risk prostate 
cancer: Preliminary results of a prospective phase II study. Int. J. 
Hyperthermia. 23(5), 451-456. 
Masselink, H., and Bernards, R. (2000). The adenovirus E1A binding protein BS69 
is a corepressor of transcription through recruitment of N-CoR. Oncogene. 
19, 1538-1546.   
Matsuda, K., Yoshida, K., Taya, Y., Nakamura, K., Nakamura, Y., and Arakawa, H. 
(2002). p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res. 
62, 2883-2889. 
Mayer, M.P., Schroder, H., Rudiger, S., Paal, K., and Laufen, T. (2000). Multistep 
mechanism of substrate binding determines chaperone activity of Hsp70. Nat. 
Struct. Biol. 7, 586-593. 
McCarty, J.S., and Walker, G.C. (1991). DnaK as a thermometer: Threonine-199 is 
site of autophosphorylation and is critical for ATPase activity. Proc. Natl. 
Acad. Sci. USA. 88, 9513-9517. 
Medical News Today. What is breast cancer? What causes breast cancer? (2015). 
Available online: 
http://www.medicalnewstoday.com/articles/37136.php (accessed on 25th 
January 2015). 
Mei, Y.F., and Wadell, G. (1996). Epitopes and hemagglutination binding domain on 
subgenus B:2 adenovirus fibers. J.Virol. 70(2), 3688-3697. 
Melo, F., and Feytmans, E. (1998). Assessing protein structures with a non-local 
atomic interaction energy. Journal of Molecular Biology. 277, 1141-1152. 
242 
 
Morris, G.M., Goodshell, D.S., Halliday, R.S., Huey, R., Hart, W.E. Belew, R.K., 
and Olson, A.J. (1998). Automated docking using a Lamarckian genetic 
algorithm and an empirical binding free energy function. J. Comp. Chem. 
19(14), 1639-1662. 
Morris, C.C., Myers, R., and Field, SB. (1977). The response of the rat tail to 
hyperthermia. The British J. Radiol. 50(596), 576-580. 
Muller, L., Schaupp, A. Walerych, D., Wegele, H., and Buchner, J. (2004). Hsp90 
regulates the activity of wild type p53 under physiological and elevated 
temperatures. J. Biol. Chem. 279, 48846-48854. 
Muss, H.B., Berry, D.A., and Cirrincione C.T. (2009). Adjuvant chemotherapy in 
older women with early-stage breast cancer. N. Engl. J. Med. 360(20), 2055-
2065. 
National Cancer Institute. (2014). Breast cancer. Available online: 
http://www.cancer.gov/cancertopics/types/breast (accessed on 1st May 2014). 
National Cancer Registry Report. (2014). Ministry of Health, Malaysia. 
Nechushtan, A., Smith, C.L., and Hsu, Y.T. (1999). Conformation of the Bax C-
terminus regulates subcellular location and cell death. EMBO J. 18, 2330-
2341. 
Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987). Negative and positive 
regulation by a short segment in the 5´-flanking region of the human 
cytomegalovirus major immediate-early gene. Mol. Cell. Biol. 7, 4125-4129. 
Netzer, W.J., and Hartl, F.U. (1998). Protein folding in the cytosol: Chaperon 
independent and -independent mechanisms. Trends Biochem. Sci. 23, 68-73. 
Niewiarowska, J., D’Halluin, J.C., and Belin, M.T. (1992). Adenovirus capsid 
proteins interact with HSP70 proteins after penetration in human or rodent 
cells. Exp. Cell Res. 201, 408-416. 
Nishiokaa, M., Mizuguchia, H., Fujiwaraa, S., Komatsubarab, S., Kitabayashib, M., 
Uemurab, H., Takagia, M., and Imanakac, T. (2001). Long and accurate PCR 
with a mixture of KOD DNA polymerase and its exonuclease deficient 
mutant enzyme. J. Biotech. 88(2), 141-149. 
O’Brien, M.C., Flaherty, K.M., and McKay, D.B. (1996). Lysine 71 of the chaperone 




Ohnishi, T., Wang, X., Ohnishi, K., and Matsumoto, H., and Takashi, A. (1996). 
p53-dependent induction of WAF1 by heat treatment in human gliblastoma 
cells. J. Biol. Chem. 271, 14510-14513. 
O’Neill, K.L., Fairbairn, D.W., Smith, M.J., and Poe, B.S. (1998). Critical 
parameters influencing hyperthermia-induced apoptosis in human lymphoid 
cell lines. Apoptosis. 3(5), 369-375. 
Overgaard, J., Gonzalez, D., Hulshof, M.C., Arcangeli, G., Dahl, O., Mella, O., and 
Bentzen, S.M. (2009). Hyperthermia as an adjuvant to radiation therapy of 
recurrent or metastatic malignant melanoma. A multicentre randomized trial 
by the European Society for Hyperthermic Oncology. 1996. Int. J. 
Hyperthermia. 25(5), 323-334. 
Pal, S., Datta, K., and Mukhopadhyay, D. (2001). Central role of p53 on regulation 
of vascular permeability factor/vascular endothelial growth factor 
(VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61, 6952-
6957. 
Pathak, R.K., Baunthiyal, M., Taj, G., and Kumar, A. (2014). Virtual screening of 
natural inhibitors to the predicted HBx protein structure of Hepatitis B Virus 
using molecular docking for identification of potential lead molecules for 
liver cancer. Bioinformation. 10(7), 428-435. 
Parvizpour, S., Shamsir, M.S., Razmara, J., Ramli, A.N.M., and Md Illias, R. (2004). 
Structural and functional analysis of a novel psychrophilic βmannanase from 
Glaciozyma Antarctica PI12. J. Comput. Aided Mol. Des. 28(6), 685-698. 
Peer, A.J., Grimm, M.J., Zynda, E.R., and Repasky, E.A. (2010). Diverse immune 
mechanisms may contribute to the survival benefit seen in cancer patients 
receiving hyperthermia. Immunol Res. 46(3), 137-154. 
Petit, T., Dufour, P., and Tannock, I. (2011).  A critical evaluation of the role of 
aromatase inhibitors as adjuvant therapy for postmenopausal women with 
breast cancer. Endocr. Relat. Cancer. 18(3), 79-89. 
Petkso, G.A., and Ringe, D. (2004). Protein Struct. & Funct. New Science Press Ltd. 
Ponce, A.M., Vujaskovic, Z., Yuan, F., Needham, D., and Dewhirst, M.W. (2006). 




Reddy, C.S., Vijayasarathy, K., Srinivas, E., Sastry, G.M., and Sastry, G.N. (2006). 
Homology modeling of membrane proteins: A critical assessment. Comput. 
Biol. Chem. 30, 120-126. 
Remm, M., Remm, A., and Ustav, M. (1999). Human papillomavirus type 18 E1 
protein is translated from polycistronic mRNA by a discontinuous scanning 
mechanism. J. Virol. 73, 3062-3070. 
Ritossa, F. (1962). A new puffing pattern induced by heat shock and DNP in 
Drosophila. Experientia. 18, 571-573. 
Romano, G., Michell, P., Pacilio, C., and Giordano, A. (2000). Latest developments 
in gene transfer technology: achievements, perspectives, and controversies 
over therapeutic applications. Stem Cells. 18, 19 -39. 
Rosenblum, M.D., Olasz, E., Woodliff, J.E., Johnson, B.D., Konkol, M.C., Gerber, 
K.A., Orentas, R.J., Sandford, G., and Truitt, R.L. CD200 is a novel p53-
target gene involved in apoptosis-associated immune tolerance. Blood. 103, 
2691-2698. 
Rother, K., Johne, C., Spiesbach, K., Haugwitz, U., Tschop, K., Wasner, M., Klein-
Hitpass, L., Moroy, T., Mossner, J., and Engeland, K. (2004). Identification 
of Tcf-4 as a transcriptional target of p53 signalling. Oncogene. 23, 3376-
3384. 
Roucou, X., Montessuit, S., Antonsson, B., and Martinou, J.C. (2002). Bax 
oligomerization in mitochondrial membranes requires tBid (caspase-8-
cleaved Bid) and a mitochondrial protein. Biochem. J. 368, 915-921. 
Roy, U., Woods, A.G., Sokolowska, I., and Darie, C.C. (2014). Structural 
investigation of HSP70-HSP90 and HSP90-TDF interactions. Mod. Chem. 
Appl. 2(2), 1-5. 
Roy, S., Maheshwari, N., Chauhan, R., Sen, N.K., and Sharma, A. (2011). Structure 
prediction and functional characterization of secondary metabolite proteins of 
Ocimum. Bioinformation, 6(8), 315-319. 
Rubanyi, G.M. (2001). The future of human gene therapy. Mol. Aspects Med. 22, 
113-142. 
Rudiger, S., Freund, S.M., Veprintsev, D.B., and Fersht, A.R. (2002). CRINEPT-
TROSY NMR reveals p53 core domain bound in an unfolded form to the 
chaperone Hsp90. Proc Natl Acad Sci. USA. 99, 11085-11090. 
245 
 
Russell, W. C. (2000). Update on Adenovirus and its Vectors. J. Gen. Virol. 81, 
2573-2604. 
Rutherford, S.L., and Zuker, C.S. (1994). Protein folding and the regulation of 
signalling pathways. Cell. 79, 1129-1132. 
Sah, N.K., Munshi, A., Nishikawa, T., Mukhopadhyay, T., Roth, J.A., and Meyn, 
R.E. (2003). Adenovirus-mediated wild-type p53 radiosensitizes human 
tumor cells by suppressing DNA repair capacity. Mol. Cancer Ther. 2, 1223-
1231. 
Sanchez, R., Pieper, U., Melo, F., Eswar, N., Marti-Renom, M.A., Madhusudhan, 
M.S., Mirkovic, N., and Sali, A. (2000). Protein structure modeling for 
structural genomics. Nature Struct. Biol. 986-990. 
Sanner, M.F. (1999). Python: A programming language for software integration and 
development. J. Mol. Graph. Model. 17, 57-61. 
Schinzel, A., Kaufmann, T., and Schuler, M. (2004). Conformational control of Bax 
localization and apoptotic activity by Pro168. J. Cell Biol. 164, 1021-1032. 
Schuler, M., Herrmann, R., and De Greve, J.L. (2001). Adenovirus-mediated wild-
type p53 gene transfer in patients receiving chemotherapy for advanced non-
small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol. 
19, 1750-1758. 
Schulz, R. (2007). Protein structure prediction. 
Shrake, A., and Rupley, J.A. (1997). Environment and exposure to solvent of protein 
atoms. Lysozyme and insulin. J. Mol. Biol. 79, 351-371. 
Shaikh, F., Sanehi, P., and Rawal, R. (2012). Molecular screening of compounds to 
the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. 
Bioinformation. 8(13), 607-612. 
Simon, M.C., Kitchener, K., Kao, H.T., Hickey, E., Weber, L., Voellmy, R., Heintz, 
N., and Nevins, J.R. (1987). Selective induction of human heat shock gene 
transcription by the adenovirus E1A gene products, including the 12S E1A 
product. Mol. Cell Biol. 7, 2884-2890. 
Skitzki, J.J., Repasky, E.A., and Evans, S.S. (2009). Hyperthermia as an 
immunotherapy strategy for cancer. Curr. Opin. Investig. Drugs. 10(6), 550-
558. 
Song, C.W., Lokshina, A., and Rhee, J.G. (1984). Implication of blood ﬂow in 
hyperthermic treatment of tumors.  IEEE Trans BME. 31, 9-16. 
246 
 
Song, C.W., Park, H., and Griffin, R.J. (2001). Improvement of tumor oxygenation 
by mild hyperthermia. Radiat. Res. 155(4), 515-528. 
Soussi, T., de Fromentel, C.C., Sturzbecher, H.W., Ullrich, S, Jenkins, J., and May 
Pierre. (1989). Evolutionary conservation of the biochemical properties of 
p53: Specific interaction of Xenopus laevis p53 with Simian Virus 40 large T 
antigen and mammalian heat shock proteins 70. J. Virol. 63(9), 3894-3901. 
Sriram, M., Osipiuk, J., Freeman, B.C., Morimoto, R.I., and Joachimiak, A. (1997). 
Human Hsp70 molecular chaperone binds two calcium ions within the 
ATPase domain. Structure. 5, 403-414. 
Steiner, T., and Koellner, G. (2001). Hydrogen bonds with p–acceptors in proteins: 
frequencies and role in stabilizing local 3-D structures. J. Mol. Biol. 305, 535-
557. 
Stellwagen, N.C. (1998). Apparent pore size of polyacrylamide gels: comparison of 
gels cast and run in Tris-acetate-EDTA and Tris-borate-EDTA buffers. 
Electrophoresis. 19(10), 1542-1547. 
Stone, D.E., and  Craig, E.A. (1990). Self-regulation of 70 kilodalton heat shock 
proteins in Saccharomyces cerevisiae. Mol. Cell Biol. 10, 1622-1632. 
Stothard, P. (2006). Sequence Extractor. Available online: 
http://www.bioinformatics.org/seqext/ (accessed on 5th March 2011). 
Strasser, A., O’Connor, L., and Dixit, V.M. (2000). Apoptosis signaling. Annu. Rev. 
Biochem. 69, 217-245. 
STRINGV9.1. Available online:  
http://string-db.org/ (accessed on 3rd February 2014). 
Sugano, T., Nitta, M., Ohmori, H., and Yamaizumi, M. (1995). Nuclear 
accumulation of p53 in normal human fibroblasts is induced by various 
cellular stresses which evoke the heat shock response, independently of the 
cell cycle. Jpn. J. Cancer Res. 86, 415-418. 
Sunamura, M., Yatsuoka, T., Motoi, F., Duda, D.G., Kimura, M., Abe, T., 
Yokoyama, T., Inoue, H., Oonuma, M., Takeda, K., and Matsuno, S. (2002). 
Gene therapy for pancreatic cancer based on genetic alterization of the 
disease. J. Hepatobililary Panncreat. Surg. 9, 32-38. 
Swain, J. F., Dinler, G., Sivendran, R., Montgomery, D. L., Stotz, M., and Gierasch, 
L. M. (2007). Hsp70 chaperone ligands control domain association via an 
247 
 
allosteric mechanism mediated by the interdomain linker. Mol. Cell. 26, 27-
39. 
Swisher, S.G., Roth, J.A., and Nemunaitis, J. (1999). Adenovirus-mediated p53 gene 
transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 763-
771. 
Swisher, S.G., Roth, J.A., and Komaki, R. (2003). Induction of p53-regulated genes 
and tumor regression in lung cancer patients after intratumoral delivery of 
adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9, 93-
101. 
Taha, T.A., Osta, W., Kozhaya, L., Bielawski, J., Johnson, K.R., Gillanders, W.E., 
Dbaibo, G.S., Hannun, Y.A., and Obeid, L.M. (2004). Downregulation of 
sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J. 
Biol. Chem. 279, 20546-20554. 
Takagi, M., Nishioka, M., Kakihara, H., Kitabayashi, M., Inoue, H., Kawakami, B., 
and Imanaka, T. (1997). Characterization of DNA polymerase from 
Pyrococcus sp. strain KOD1 and its application to PCR. Appl. Environ. 
Microbiol. 63(11), 4504-4510. 
Takasu, T., Lyons, J.C., Park, H.J., and Song, C.W. (1998). Apoptosis and 
perturbation of cell cycle progression in an acidic environment after 
hyperthermia. Cancer Res. 58(12), 2504-2508.  
Thorne, S.H., Brooks, G., Lee, Y.L., Au, T., Eng, L.F., and Reid, T. (2005). Effects 
of febrile temperature on adenoviral infection and replication: Implications 
for viral therapy of cancer. J. Virol. 79, 581-591. 
Thrall, D.E., Larue, S.M., Pruitt, A.F., Case, B., and Dewhirst, M.W. (2006). 
Changes in tumour oxygenation during fractionated hyperthermia and 
radiation therapy in spontaneous canine sarcomas. Int. J. Hyperthermia. 
22(5), 365-373. 
Urano, M., Rice, L., and Epstein, R. (1983). Effect of whole-body hyperthermia on 
cell survival, metastasis frequency, and host immunity in moderately and 
weakly immunogenic murine tumors. Cancer Res. 43(3), 1039-1043. 
van der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., and Berendsen, 




van der Zee, J., van der Holt, B., and Rietveld, P.J. (1999). Reirradiation combined 
with hyperthermia in recurrent breast cancer results in a worthwhile local 
palliation. Br. J. Cancer. 79, 483-490. 
van der Zee, J. (2002). Heating the patient: A promising approach? Ann. 
Oncol:ESMO. 13, 1173-1184. 
van der Zee, J. (2008). The Kadota Fund International Forum 2004--clinical group 
consensus. Int. J. Hyperthermia. 24(2), 111-122. 
van der Zee, J., De Bruijne, M., Mens, J.W., Ameziane, A., Broekmeyer-Reurink, 
M.P., Drizdal, T., Linthorst, M., and Van Rhoon, G.C. (2010). Reirradiation 
combined with hyperthermia in breast cancer recurrences: overview of 
experience in Erasmus MC. Int. J. Hyperthermia. 26(7), 638-648. 
van Gunsteren, W. (1996). Biomolecular simulations: The GROMOS96 manual and 
user guide. VdF Hochschulverlag ETHZ. 
Vasconcelos, D.Y., Cai, X.H., and Oglesbee, M.J. (1998). Constitutive 
overexpression of the major inducible 70 kDa heat shock protein mediates 
large plaque formation by measles virus. J. Gen. Virol. 79, 2239-2247. 
Vogel, M., Bukau, B., and Mayer, M. P. (2006). Allosteric regulation of Hsp70 
chaperones by a proline switch. Mol. Cell.  21, 359-367. 
Vogelstein, B. (1990). A deadly inheritance. Nature. 348, 681-682. 
Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature. 
408, 307-310. 
Wallner, B., and Elofsson, A. (2003). Can correct protein models be identified? 
Protein Sci. 12, 1073-1086. 
Walters, R.W., Grunst, T., Bergelson, J.M., Finberg, R.W., Welsh, M.J., and Zabner, 
J. (1999). Basolateral localization of fiber receptors limits adenovirus 
infection from the apical surface of airway epithelia. J. Biol. Chem. 274, 
10219-10226. 
Walther, W., and Stein, U. (2009). Heat-responsive gene expression for gene 
therapy. Adv. Drug Deliv. Rev. 61(7-8), 641-649. 
Watanabe, M., and Suzuki, K. (1989). Heat sensitivity of human cancer cells and 




Watanabe, T., Kuszynski, C., and Ino, K. (1996). Gene transfer into human bone 
marrow hematopoietic cells mediated by adenovirus vectors. Blood. 87, 
5032-5039. 
Wawrzynow, A., Banecki, B., Wall, D., Liberek, K., and Georgopoulos, C. (1995). 
ATP hydrolysis is required for the DnaJ-dependent activation of DnaK 
chaperone for binding to both native and denatured protein substrates. J. Biol. 
Chem. 270, 19307-19311. 
Weiss, M.S., Brandl, M., Sühnel, J., Pal, D., and Hilgenfeld, R. (2001). More 
hydrogen bonds for the (structural) biologist. Trends Biochem. Sci. 26, 521-
523. 
White, E., Spector, D., and Welch, W. (1988). Differential distribution of the 
adenovirus E1A proteins and colocalization of E1A with the 70-kilodalton 
cellular heat shock protein in infected cells. J. Virol. 62, 4153-4166. 
Wickner, S., Skowyra, D., Hoskins, J., and Mckenney, K. (1992). DnaJ, DnaK, and 
GrpE heat shock proteins are required in oriP1 DNA replication solely at the 
RepA monomerization step. Proc. Natl. Acad. Sci. USA. 89, 10345-10349. 
Wiederstein, M., and Sippl, M. (2007). ProSA-web: interactive web service for the 
recognition of errors in three-dimensional structures of proteins. Nucleic 
Acids Res. 35, W407-410. 
Williams, R.S., Thomas, J.A., and Fina, M. (1993). Human heat shock protein 70 
(hsp70) protects murine cells from injury during metabolic stress. The J. Clin. 
Invest. 92(1), 503-508. 
World Health Organization (WHO). (2014). Available online: 
http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed on 1st May 
2014). 
Wolff, S., Erster, S., Palacios, G., and Moll, U.M. (2008). p53’s mitochondrial  
translocation and MOMP action is independent of Puma and Bax and 
severely disrupts mitochondrial membrane integrity. Cell Res. 18(7), 733-
744. 
Wu, G.S., Burns, T.F., McDonald, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., 
Gan, D.D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., 
Markowitz, S., Wu, G., and el-Deiry, W.S. (1997). KILLER/DR5 is a DNA 




Xu, M., Myerson, R.J., Xia, Y., Whitehead, T., Moros, E.G., Straube, W.L., and Roti 
Roti, J.L. (2007). The effects of 41°C hyperthermia on the DNA repair 
protein, MRE11, correlate with radiosensitization in four human tumor cell 
lines. Int. J. Hyperthermia. 23(4), 343-351. 
Yamamoto, M., and Curiel, D.T. (2010). Current issues and future directions of 
oncolytic adenoviruses, Mol. Ther. 18, 243-250. 
Yin, Y., Liu, Y.X., Jin, Y.J., Hall, E.J., and Barrett, J.C. (2003). PAC1 phosphatase is 
a transcription target of p53 in signaling apoptosis and growth suppression. 
Nature.  422, 527-531. 
Yonezawa M., Otsuka T., Matsui N., Tsuji H., Kato K.H., and Moriyama A. (1996). 
Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in 
vitro. Int. J. Cancer. 66(3), 347-351. 
Zhou, B. P. (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced 
phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3, 245-
252. 
Zou, H., Henzel, W.J., Liu, X., Lutschg, A., and Wang, X. (1997). Apaf-1, a human 
protein homologous to C. elegans CED-4, participates in cytochrome c- 
dependent activation of caspase-3.Cell. 90, 405-413.  
 
